Article

IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex.

Discovery Research, Schering-Plough Biopharma (formerly DNAX Research), Palo Alto, CA 94304, USA.
The Journal of Immunology (Impact Factor: 5.36). 09/2007; 179(4):2551-5. DOI: 10.4049/jimmunol.179.4.2551
Source: PubMed

ABSTRACT IL-33 (IL-1F11) is a recently described member of the IL-1 family of cytokines that stimulates the generation of cells, cytokines, and Igs characteristic of a type 2 immune response. IL-33 mediates signal transduction through ST2, a receptor expressed on Th2 and mast cells. In this study, we demonstrate that IL-33 and ST2 form a complex with IL-1R accessory protein (IL-1RAcP), a signaling receptor subunit that is also a member of the IL-1R complex. Additionally, IL-1RAcP is required for IL-33-induced in vivo effects, and IL-33-mediated signal transduction can be inhibited by dominant-negative IL-1RAcP. The implications of this shared usage of IL-1RAcP by IL-1(alpha and beta) and IL-33 are discussed.

0 Followers
 · 
158 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Interleukin (IL)-33 signals influence various immune cells during differentiation, immune responses and homeostasis. As discussed in this Review, IL-33 via TI/ST2L regulates the functions of immune cells including T cells, B cells, DCs, macrophages, mast cells, and innate lymphoid cells (ILCs). Stimulation with IL-33 is crucial for CD4+ T cell polarized into Th2 immunity and for the induction of Treg. CD8+ T cells can also express ST2L and IL-33 promotes features of effector CD8+ T cells. For macrophages and ILCs, ST2L presents on these cells and IL-33 induces Th2 cytokine production. IL-33 modulates adhesion, activation, maturation, and cytokine production by mast cells. ST2 is expressed in B1 and is important for differentiation of IL-10-producing B cells. Understanding the specific role of IL-33/ST2L in different immune cells will help to answer the remaining questions that are important for diseases pathologies and intervention strategies by targeting the IL-33/ST2L signals.
    Immunology Letters 02/2015; 179(1). DOI:10.1016/j.imlet.2015.01.008 · 2.37 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Interleukin-33 (IL-33) is a member of the interleukin-1 cytokine family and highly expressed in the naïve mouse brain and spinal cord. Despite the fact that IL-33 is known to be inducible by various inflammatory stimuli, its cellular localization in the central nervous system and role in pathological conditions is controversial. Administration of recombinant IL-33 has been shown to attenuate experimental autoimmune encephalomyelitis progression in one study, yet contradictory reports also exist. Here we investigated for the first time the pattern of IL-33 expression in the contused mouse spinal cord and demonstrated that after spinal cord injury (SCI) IL-33 was up-regulated and exhibited a nuclear localization predominantly in astrocytes. Importantly, we found that treatment with recombinant IL-33 alleviated secondary damage by significantly decreasing tissue loss, demyelination and astrogliosis in the contused mouse spinal cord, resulting in dramatically improved functional recovery. We identified both central and peripheral mechanisms of IL-33 action. In spinal cord, IL-33 treatment reduced the expression of pro-inflammatory tumor necrosis factor-alpha and promoted the activation of anti-inflammatory arginase-1 positive M2 microglia/macrophages, which chronically persisted in the injured spinal cord for up to at least 42days after the treatment. In addition, IL-33 treatment showed a tendency towards reduced T-cell infiltration into the spinal cord. In the periphery, IL-33 treatment induced a shift towards the Th2 type cytokine profile and reduced the percentage and absolute number of cytotoxic, tumor necrosis factor-alpha expressing CD4+ cells in the spleen. Additionally, IL-33 treatment increased expression of T-regulatory cell marker FoxP3 and reduced expression of M1 marker iNOS in the spleen. Taken together, these results provide the first evidence that IL-33 administration is beneficial after CNS trauma. Treatment with IL33 may offer a novel therapeutic strategy for patients with acute contusion SCI.
    Brain Behavior and Immunity 08/2014; · 6.13 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Interleukin-33 (IL-33) is a recently described member of the IL-1 family. IL-33 acts as an alarmin, chemoattractant, and nuclear factor. ST2, a member of the Toll-like receptor/IL-1R superfamily, the receptor of IL-33, triggers a plethora of downstream effectors and leads the activation of NFK-B, leading the expression of several genes. IL-33 and ST2 are expressed in the majority of cell types, and the IL-33/ST2 axis has a role in immune response, bone homeostasis, and osteoclastogenesis. Several studies show opposite roles of IL-33 in osteoclastogenesis and the implication in bone biology. Few works studied the role of IL-33 in periodontal disease, but we hypothesize a possible role of IL-33 in periodontal disease and bone loss.
    Mediators of Inflammation 02/2014; 2014:342410. DOI:10.1155/2014/342410 · 2.42 Impact Factor

Preview (2 Sources)

Download
1 Download
Available from